23 Stock Top Picks and 7 ETF (Nov 30 Dec 6)

All the new models of phones on the market will support 5G, including Apple's, and there will be lots of phone upgrades. He hopes Apple breaks out the lifetime value of their customers this quarter, thanks to this sticky revenue stream.

They report Thursday. He expects them to tell a good story. It would benefit from cross-border travel.

Hard to say which one would perform the best in a correction. ZZZD has a very defensive posture with half of the portfolio hedged to downside risk. ZWU and ZPAY are in ZZZD. Would look to be defensive in the next few months.

(A Top Pick Dec 04/18, Up 2%) Safety play. A place to park cash. Never touches a GIC, because they're not liquid.

Still buying this. Companies have so much cash that they will raise their dividends. There are also many solid companies like P&G and JNJ. 0.3% MER. Earlier this year, when growth stocks rallied, dividend stocks lagged, but that has since changed. See also his past picks.

Many are worried that rates will rise but he doesn't expect them to in the near-term so XLP.

If you are getting exposure to US energy, he expects US pipelines to be at capacity so playing it through the MLP is a good strategy. The dividend cut was in response to the pressure on energy price. He owns for the yield and not cap gains.

Good momentum. Basket of commercial, residential, storage, and so on. Issue is the expensive valuation. Another way to play it is to look at the US homebuilders, such as ITB, his preference, which also has a home renovation component. Supply/demand dynamics speak to years and years of home building.

Long-term, really likes the sector. When things are hot, the sector may lag. XLV has about 65 names. Aging demographics, growing emerging markets and middle class, increased healthcare spending. This year, healthcare ranks #8 out of 11 sectors. But if you're concerned about the long term, which he thinks you should be, XLV is a…

Owns these two banks. BNS is Canadian and Latin America, where as RBC is Canada and US. Likes BNS's exposure to Latin America. Currently under covid, it is being more hurt. The stock is lagging here because of this. RBC is doing better due to Canada and US doing better. Over the long term, RBC…

Specialty insurance. Spun out of one of the Brookfields. US business, called fronting, is very exciting, and it crosses state lines. Growth profile is fantastic. High and growing ROEs, growing access to capital, dynamic CEO. No dividend. (Analysts’ price target is $178.13)

(A Top Pick Dec 04/18, Up 32%) Great tech ETF.

Owns these two banks. BNS is Canadian and Latin America, where as RBC is Canada and US. Likes BNS's exposure to Latin America. Currently under covid, it is being more hurt. The stock is lagging here because of this. RBC is doing better due to Canada and US doing better. Over the long term, RBC…

Share count keeps falling. Massive free cashflow, 12x earnings, dividend growth well above average. Premier company in their field. Houses, cars, and now getting into protection for smartphones and the like. Rising interest rates are a benefit, though they've been thriving with low interest rates. Yield is 2.39%. (Analysts’ price target is $138.87)

(A Top Pick Jun 25/20, Up 73.38%) Still bullish. A good citizen during pandemic, by not passing on rent increases to residents. Positive cashflow last year continuing into this year. Balance sheet cleaned up, lots of capital on hand. Still trades at discount to NAV.

(A Top Pick Dec 05/18, Up 45%) It's a Blackstone-sponsored company that bought a bunch of single-family homes and rent them out. Blackstone IPO'd this and sold it in tranches over time. Now, the stock has legs and doesn't need the parent's support. They rent to tenants and are adding ancillary businesses, like pet services…

Admires the management, but he doesn't like commercial office space now, but ARE's tenants are American biotech and life science companies, which carry the costs of. A lot of value here.

He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has…

Kudos to the new executive at delevering and cleaning things up. Inexpensive valuation. Still a lot of debt. A turnaround story. 3% of your portfolio is a bit heavy. Add some diversity. Had a great move. Be cautious.

They report Thursday. Healthcare so far is avoiding Biden's anti-trust efforts. The stock is over $400, but it's still viable. He foolishly sold his shares earlier.

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

MRK vs. ABT Both are great companies. ABT is the leading supplier of glasswork to the medical industry. Merck has incredible products as a global pharmaceutical company. You could buy either one.

You want to buy it when it's on sale. A bit rich here. The diagnostics is an area of growth, but we'll have to wait and see. Hold, if you have a good entry point. Good quality company longer term. Not a buyer at this point.

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

Winnipeg busmaker was once a Bay Street darling, then production numbers tanked before Covid sent the stock went into purgatory. Emerging from the lockdown, though, NFI is now in a good position to capitalize on the e-vehicle trend. The busmaker is rolling out more zero-emission vehicles, which cities across North American will favour under the…

World leaders in nuclear valves. Has become more shareholder friendly, focusing on higher margins and more profitable areas. Record backlogs, so this year should be very strong. Nominated first non-family chairman ever, a positive. Significantly below tangible book value. His firm is pushing to unlock shareholder value. Support at these levels and should go higher.

(A Top Pick Jun 02/20, Up 26%) A Japanese company, a leader in test equipment. They are incredibly well positioned without a lot of competition. A global leader. They have zero debt.

It is an interesting business. It is specialty pharmacies. They do medication for long term care facilities. They have an interesting pouch technology. They had quite a significant debt load and made a big dent in it when they sold their surgical business. They are trying to pick up new contracts. He has owned it…

A few years ago, he though the PE was stretched, but is better now and he's taking a close look at it. It suddenly jumped from $44 to $49. Very well-managed. They were put in the penalty box when they tried to buy Carrefour. They're planning to add fresher food in their stores. It's an…

Execution has always been an issue for them. The streets are worried about their ability so this is why it trades at a discount. Stock is inexpensive at 3.6x cashflow with a 19% free cashflow yield. If you want to stick in the large cap realm, he prefers Cenovus. Could trade at a discount for…